Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2007 2
2008 1
2009 6
2010 7
2011 7
2012 6
2013 3
2014 6
2015 5
2016 7
2017 7
2018 8
2019 8
2020 2
2021 6
2022 7
2023 8
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Mellinghoff IK, et al. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272516 Free PMC article. Clinical Trial.
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. Omuro A, et al. Among authors: vauleon e. Neuro Oncol. 2023 Jan 5;25(1):123-134. doi: 10.1093/neuonc/noac099. Neuro Oncol. 2023. PMID: 35419607 Free PMC article. Clinical Trial.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, Miroir J, Kaminsky MC, Coutte A, Liem X, Chautard E, Vauleon E, Drouet F, Ruffier A, Ramee JF, Waksi G, Péchery A, Wanneveich M, Guigay J, Aupérin A, Bourhis J. Tao Y, et al. Among authors: vauleon e. Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28. Ann Oncol. 2023. PMID: 36522816 Free article. Clinical Trial.
Dual IRE1 RNase functions dictate glioblastoma development.
Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, Pineau R, Obacz J, Papadodima O, Jouan F, Bourien H, Logotheti M, Jégou G, Pallares-Lupon N, Schmit K, Le Reste PJ, Etcheverry A, Mosser J, Barroso K, Vauléon E, Maurel M, Samali A, Patterson JB, Pluquet O, Hetz C, Quillien V, Chatziioannou A, Chevet E. Lhomond S, et al. Among authors: vauleon e. EMBO Mol Med. 2023 Feb 8;15(2):e16731. doi: 10.15252/emmm.202216731. EMBO Mol Med. 2023. PMID: 36752056 Free PMC article.
Rethinking Alkylating(-Like) Agents for Solid Tumor Management.
Lajous H, Lelièvre B, Vauléon E, Lecomte P, Garcion E. Lajous H, et al. Among authors: vauleon e. Trends Pharmacol Sci. 2019 May;40(5):342-357. doi: 10.1016/j.tips.2019.03.003. Epub 2019 Apr 9. Trends Pharmacol Sci. 2019. PMID: 30979523 Free article. Review.
Beneath HMGA2 alterations in pleomorphic adenomas: Pathological, immunohistochemical, and molecular insights.
Alsugair Z, Lépine C, Descotes F, Lanic MD, Pissaloux D, Tirode F, Lopez J, Céruse P, Philouze P, Fieux M, Wassef M, Baglin AC, Mihaela O, Castain C, Sudaka A, Uro-Coste E, Champagnac A, Costes-Martineau V, Laé M, Benzerdjeb N; REFCOR network*. Alsugair Z, et al. Hum Pathol. 2024 Oct;152:105633. doi: 10.1016/j.humpath.2024.105633. Epub 2024 Jul 30. Hum Pathol. 2024. PMID: 39089476 Free article.
Dual IRE1 RNase functions dictate glioblastoma development.
Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, Pineau R, Obacz J, Papadodima O, Jouan F, Bourien H, Logotheti M, Jégou G, Pallares-Lupon N, Schmit K, Le Reste PJ, Etcheverry A, Mosser J, Barroso K, Vauléon E, Maurel M, Samali A, Patterson JB, Pluquet O, Hetz C, Quillien V, Chatziioannou A, Chevet E. Lhomond S, et al. Among authors: vauleon e. EMBO Mol Med. 2022 Feb 7;14(2):e15622. doi: 10.15252/emmm.202115622. Epub 2022 Jan 11. EMBO Mol Med. 2022. PMID: 35014200 Free PMC article.
88 results